Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers

Emerging evidence suggests a role of receptor activator of nuclear factor κB (RANK)/RANK ligand (RANKL) signaling in breast cancer development. Lower osteoprotegerin (OPG) levels, the endogenous decoy receptor for RANKL which competes with RANK for binding of RANKL, has been reported among BRCA muta...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Odén, Lovisa, Akbari, Mohammad, Zaman, Tasnim, Singer, Christian F., Sun, Ping, Narod, Steven A., Salmena, Leonardo, Kotsopoulos, Joanne
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2016
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5349945/
https://ncbi.nlm.nih.gov/pubmed/27893411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13417
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items